Jatin J. Shah

10.1k total citations
208 papers, 3.8k citations indexed

About

Jatin J. Shah is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jatin J. Shah has authored 208 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Hematology, 115 papers in Molecular Biology and 88 papers in Oncology. Recurrent topics in Jatin J. Shah's work include Multiple Myeloma Research and Treatments (143 papers), Protein Degradation and Inhibitors (66 papers) and Cancer Treatment and Pharmacology (39 papers). Jatin J. Shah is often cited by papers focused on Multiple Myeloma Research and Treatments (143 papers), Protein Degradation and Inhibitors (66 papers) and Cancer Treatment and Pharmacology (39 papers). Jatin J. Shah collaborates with scholars based in United States, Spain and Canada. Jatin J. Shah's co-authors include Robert Z. Orlowski, Sheeba K. Thomas, Donna M. Weber, Michael Wang, Narayan Sundaresan, Muzaffar H. Qazilbash, Kathleen M. Foley, Gerald Rosen, Rafat Abonour and Jonathan L. Kaufman and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jatin J. Shah

203 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jatin J. Shah United States 31 2.4k 2.0k 1.6k 553 417 208 3.8k
Dixie Esseltine United States 22 1.8k 0.8× 1.9k 0.9× 1.6k 1.0× 506 0.9× 539 1.3× 44 3.1k
Niklas Zojer Austria 26 1.7k 0.7× 1.8k 0.9× 1.1k 0.7× 245 0.4× 474 1.1× 125 2.7k
Donna M. Weber United States 28 2.4k 1.0× 2.7k 1.3× 1.6k 1.0× 413 0.7× 616 1.5× 132 3.6k
H M Lokhorst Netherlands 35 1.7k 0.7× 2.3k 1.1× 1.5k 1.0× 177 0.3× 402 1.0× 80 3.6k
Peter Gimsing Denmark 31 1.9k 0.8× 2.1k 1.0× 1.4k 0.9× 176 0.3× 301 0.7× 111 3.1k
Lugui Qiu China 27 1.5k 0.6× 1.4k 0.7× 1.3k 0.8× 522 0.9× 503 1.2× 255 2.9k
Tibor Kovacsovics United States 29 1.4k 0.6× 2.3k 1.1× 880 0.6× 261 0.5× 639 1.5× 123 3.7k
Anna Marina Liberati Italy 31 1.1k 0.5× 1.3k 0.6× 1.9k 1.2× 1.3k 2.4× 689 1.7× 148 3.8k
Eyal C. Attar United States 32 2.1k 0.9× 2.3k 1.2× 949 0.6× 262 0.5× 994 2.4× 117 4.5k
Albrecht Reichle Germany 27 1.0k 0.4× 1.4k 0.7× 1.8k 1.1× 657 1.2× 429 1.0× 125 3.8k

Countries citing papers authored by Jatin J. Shah

Since Specialization
Citations

This map shows the geographic impact of Jatin J. Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jatin J. Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jatin J. Shah more than expected).

Fields of papers citing papers by Jatin J. Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jatin J. Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jatin J. Shah. The network helps show where Jatin J. Shah may publish in the future.

Co-authorship network of co-authors of Jatin J. Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Jatin J. Shah. A scholar is included among the top collaborators of Jatin J. Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jatin J. Shah. Jatin J. Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Patel, Krina K., Jatin J. Shah, Hans C. Lee, et al.. (2022). Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clinical Cancer Research. 28(7). 1277–1284. 7 indexed citations
3.
Xu, Hongmei, Hanbin Li, Justin Bader, et al.. (2021). Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology. 88(1). 69–79. 4 indexed citations
4.
Gounder, Mrinal M., Albiruni R. Abdul Razak, Adrienne M. Gilligan, et al.. (2021). Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma. Future Oncology. 17(22). 2923–2939. 13 indexed citations
5.
Kaufman, Jonathan L., Roberto Mina, Jatin J. Shah, et al.. (2020). Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(12). 797–803. 5 indexed citations
6.
Bhatnagar, Bhavana, Sanjay Mohan, William Senapedis, et al.. (2019). Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 2997–2997. 4 indexed citations
7.
Patel, Krina K., Jatin J. Shah, Lei Feng, et al.. (2017). Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood. 130. 437–437. 12 indexed citations
8.
Li, Yan, Xiaomin Wang, Edward O’Mara, et al.. (2017). Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clinical Pharmacology Advances and Applications. Volume 9. 133–145. 10 indexed citations
9.
10.
11.
Jones, Richard J., Tawin Iempridee, Xiaobin Wang, et al.. (2016). Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clinical Cancer Research. 22(19). 4901–4912. 39 indexed citations
12.
Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43. 162 indexed citations
13.
Kuiatse, Isere, Veerabhadran Baladandayuthapani, Heather Lin, et al.. (2015). Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clinical Cancer Research. 21(11). 2538–2545. 16 indexed citations
14.
Vaklavas, Christos, Ruby F. Meredith, Sui Shen, et al.. (2013). Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 28(5). 370–379. 3 indexed citations
15.
Shah, Jatin J.. (2013). Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.. PubMed. 27 Suppl 3. 19–23. 7 indexed citations
16.
Ma, Wencai, Michael Wang, Zhiqiang Wang, et al.. (2010). Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiology Biomarkers & Prevention. 19(10). 2445–2452. 35 indexed citations
17.
Forero‐Torres, Andres, Mansoor N. Saleh, J. Galleshaw, et al.. (2010). Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer. Clinical Breast Cancer. 10(4). 275–280. 29 indexed citations
18.
Forero‐Torres, Andres, Jatin J. Shah, Tina E. Wood, et al.. (2010). Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5). Cancer Biotherapy and Radiopharmaceuticals. 25(1). 13–19. 116 indexed citations
19.
Triozzi, Pierre L., Jatin J. Shah, Wayne Aldrich, et al.. (2006). Anti-GD3 Monoclonal Antibody Effects on Lymphocytes and Antibody-Dependent Cellular Cytotoxicity. Cancer Biotherapy and Radiopharmaceuticals. 21(6). 553–560. 5 indexed citations
20.
Forero, Andres, et al.. (2006). A Phase I Study of an Anti-GD3 Monoclonal Antibody, KW-2871, in Patients with Metastatic Melanoma. Cancer Biotherapy and Radiopharmaceuticals. 21(6). 561–568. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dixie Esseltine Breakdown of academic impact, for papers by Niklas Zojer Breakdown of academic impact, for papers by Donna M. Weber Breakdown of academic impact, for papers by H M Lokhorst Breakdown of academic impact, for papers by Peter Gimsing Breakdown of academic impact, for papers by Lugui Qiu Breakdown of academic impact, for papers by Tibor Kovacsovics Breakdown of academic impact, for papers by Anna Marina Liberati Breakdown of academic impact, for papers by Eyal C. Attar Breakdown of academic impact, for papers by Albrecht Reichle
Rankless by CCL
2026